论文信息 - PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057. - 字舞流文

PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057.

H. Dastani | R. Gralla | J. Penrod | D. Spigel | B. Bennett | M. Reck | M. Derosa | C. Mathias | L. Orsini | F. Taylor